Powder: -20°C for 3 years | In solvent: -80°C for 1 year
N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride (N-alpha-Tosyl-L-lysine_chloromethyl_ketone_hydrochloride) 是胰蛋白酶样蛋白酶的抑制剂。 N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride 对 IFN-γ 活性具有抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 363 | 现货 | ||
10 mg | ¥ 597 | 现货 | ||
25 mg | ¥ 983 | 现货 | ||
50 mg | ¥ 1,473 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 463 | 现货 |
产品描述 | N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride (N-alpha-Tosyl-L-lysine_chloromethyl_ketone_hydrochloride) is an inhibitor of trypsin-like protease. N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride exhibits an inhibitory effect on IFN-γ activities. |
体外活性 | A lower concentration of anti-Fas (10 ng/mL) is used to examine the interaction among the three effectors simultaneously, that is, anti-Fas, TLCK, and IFN-γ. N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride (50 μM) exhibits a small decrease in cell viability. Beyond 50 μM, a dose-dependent decrease in cell viability is observed. IFN-γ slightly reduces cell viability on its own. The addition of anti-Fas (10 ng/mL) results in a slight decrease in cell survival, which is enhanced more than additively in the presence of TLCK, most prominently between 50 and 100 μM. Upon addition of both anti-Fas and IFN-γ, a decrease (≈46%) in cell viability is observed. Moreover, the decrease in cell survival is further enhanced by the addition of higher concentrations of TLCK, 25 μM, and more[1]. |
别名 | N-alpha-Tosyl-L-lysine_chloromethyl_ketone_hydrochloride |
分子量 | 369.31 |
分子式 | C14H22Cl2N2O3S |
CAS No. | 4272-74-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 95 mg/mL(257.24 mM), Sonication is recommended.
DMSO: 245 mg/mL (663.40 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.7078 mL | 13.5388 mL | 27.0775 mL | 67.6938 mL |
5 mM | 0.5416 mL | 2.7078 mL | 5.4155 mL | 13.5388 mL | |
10 mM | 0.2708 mL | 1.3539 mL | 2.7078 mL | 6.7694 mL | |
20 mM | 0.1354 mL | 0.6769 mL | 1.3539 mL | 3.3847 mL | |
50 mM | 0.0542 mL | 0.2708 mL | 0.5416 mL | 1.3539 mL | |
100 mM | 0.0271 mL | 0.1354 mL | 0.2708 mL | 0.6769 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride 4272-74-6 Immunology/Inflammation Neuroscience Others Proteases/Proteasome Ubiquitination Proteasome COX Inhibitor N-alpha-Tosyl-L-lysine_chloromethyl_ketone_hydrochloride inhibit N alpha Tosyl L lysine chloromethyl ketone hydrochloride NalphaTosylLlysine chloromethyl ketone hydrochloride inhibitor